Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

Snap’s flagship product is the smartphone app Snapchat, which allows its users to communicate via ephemeral short videos and ...

Thanks to a new unified hardware architecture based on Arm CPU cores, R-Car Gen 5 developers can reuse the same software and tools and applications from Renesas' broad line of new 64-bit SoCs and ...

At an event hosted by BioPharma Dive, drugmaker executives and investors discussed the importance of focus, smart spending ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

Amidst a (r)evolution in pharmaceutical strategy, Real World Evidence is more than ever a key driver of growing innovation in product life ... the full expert speaker line-up and content-packed ...

Oil and gas major Shell on Tuesday won an appeal against a landmark ruling that required it to accelerate carbon reduction ...

Several key players are shaping the global pruritus therapeutics market. Companies such as Allergan Inc., Amgen Inc., Astellas Pharma Inc., CARA Therapeutics, Novartis AG, and Teva Pharmaceutical ...

We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at ...